• Immune-Onc Therapeutics

  Participated · Series A · Sep 2016

  Immune-Onc Therapeutics is a private, clinical-stage cancer immunotherapy company developing novel myeloid checkpoint inhibitors targeting the LILRB family. Its lead clinical candidates are IO-108, an antagonist antibody targeting LILRB2 (ILT4) in Phase 1 for advanced solid tumors, and IO-202, a first-in-class antagonist antibody targeting LILRB4 (ILT3) in Phase 1 for AML, CMML and solid tumors. Additional pipeline assets include IO-106 (a LAIR1 antagonist), IO-312 (a bispecific targeting LILRB4) and multiple undisclosed programs. The company has collaborations and supply agreements with Regeneron and BeiGene to evaluate IO-108 and IO-202 in combination with anti-PD-1 therapies, and has received research grants from the NCI and CIRM. Headquartered in Palo Alto, California, Immune-Onc has also received strategic investment from The Leukemia & Lymphoma Society’s Therapy Acceleration Program (LLS TAP) and Wuxi Biologics HealthCare Venture. Management highlighted ongoing clinical milestones including dose escalation and expansion cohorts, FDA Fast Track designation for IO-202 in relapsed or refractory AML, and plans to further characterize biomarkers and mechanisms of action. Immune-Onc Therapeutics is a clinical-stage cancer immunotherapy company focused on developing novel biotherapeutics that target immunosuppressive myeloid checkpoints, specifically the LILRB family. Its lead program, IO-202, is a first-in-class antibody against LILRB4 (ILT3) being developed for acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and solid tumors; preclinical data indicate it can activate T-cell killing and enhance tumor cell detection. IO-202 entered a Phase I trial in September 2020 for AML with monocytic differentiation and CMML and received FDA Orphan Drug Designation for AML in October 2020. The company’s IO-108, an antagonist antibody targeting LILRB2 (ILT4), is in the IND‑enabling stage with plans to submit an IND in mid‑2021; other preclinical assets include IO-106 (anti-LAIR1) and multiple undisclosed programs. Immune-Onc has invested in proprietary models, assays and tools to interrogate myeloid biology and maintains strategic research collaborations with The University of Texas, Albert Einstein College of Medicine, and Memorial Sloan Kettering Cancer Center. Financially, the company has raised over $110 million since beginning operations in 2016 and is advancing its pipeline toward additional clinical milestones using newly raised capital. Immune-Onc Therapeutics is focused on the discovery and development of novel biologic treatments that target the tumor microenvironment and immune suppressive pathways. The company aims to translate unique scientific insights into first-in-class biotherapeutics and has a pipeline built on collaborations with The University of Texas, Albert Einstein College of Medicine, and Memorial Sloan Kettering Cancer Center. Headquartered in Palo Alto, California, Immune-Onc is preparing to move from translational research into the clinic. To support that transition it received Series B funding of more than $33 million to advance its pipeline programs. The company recently appointed Dr. Adrian Jubb as Chief Medical Officer and Dr. An Song as Senior Vice President of Development Sciences to lead clinical, regulatory, and translational development efforts. Immune-Onc describes a leadership team with deep drug-development experience drawn from leading biotechnology and pharmaceutical organizations. Immune-Onc Therapeutics is a Palo Alto, CA-based biopharmaceutical company co-founded in 2016 by Charlene Liao, Ph.D., and Guo-Liang Yu, Ph.D. The company focuses on discovering and developing novel therapeutic antibodies for cancer treatment. It applies scientific insights and drug-development expertise to advance immuno-oncology products. Immune-Onc plans to use its new financing to support discovery and development activities for its antibody programs. In June 2016 it raised $7M in a Series A to provide initial funding to advance its pipeline.

• Eonite Perception

  Participated · Seed · May 2016

  Eonite Perception develops a 3D mapping and ego-tracking system that uses commodity dense depth sensors to enable sub-millimeter accuracy, low latency, and robust global localization. The company launched with two products: Vantage Head Tracker™, an inside-out 6‑DoF positional tracking system for tethered and mobile VR/AR headsets that runs at very low latency on a mobile-class CPU, and Reality Insight™ SDK, a home-scale real-time 3D scanning and reconstruction SDK with a Unity plugin supporting persistent virtual content, occlusions, and shadows. Its technology is positioned for VR/AR and broader machine-perception applications such as drones and autonomous vehicles, and the company emphasizes bringing these solutions to market. Eonite highlights research provenance from founders with robotics and perception backgrounds and lists advisors including Gary Bradski and Oussama Khatib. The company recently completed a $5.25 million seed equity financing led by a group of Silicon Valley VCs and angels to support product development and commercialization.

• Aria Pharmaceuticals

  Participated · Seed · Nov 2015

  twoXAR operates a proprietary AI-driven discovery platform that identifies promising drug candidates in weeks rather than years and reports in vivo success rates significantly greater than traditional approaches. The company is building a pipeline of novel, proprietary drug candidates through partnerships with biopharmaceutical companies, drug developers, and investors. twoXAR has demonstrated candidate activity across therapeutic areas including liver cancer, rheumatoid arthritis, and type 2 diabetes. Proceeds from the new financing will be used to build the company’s drug pipeline through partnerships and accelerate preclinical development of existing candidates. The team in Palo Alto includes experts in drug discovery, biomedical informatics, computational biology, data science, and software development. twoXAR emphasizes translating computational hits into de‑risked preclinical programs and advancing them to the clinic through industry collaborations. twoXAR is a Palo Alto company advancing a digital approach to drug discovery through its DUMA™ platform. Its patent-pending algorithms evaluate massive public and proprietary datasets to identify and rank high-probability drug–disease matches faster than wet-lab approaches. These matches are used to prioritize existing candidates, perform targeted searches, and identify novel drug candidates for further clinical testing. twoXAR has identified multiple candidates that are currently in preclinical studies in collaboration with patient advocacy groups, academic researchers, and biopharmaceutical organizations. The technology has been tested on more than 20 diseases to date. The company raised $3.4M in seed financing to expand engineering and commercial teams and to advance partnerships focused on metabolic and neurological disease candidates.

No current team members are available.